Table 3.

Baseline and posttreatment correlative marker measurements

nMedian baseline level (range)Median posttreatment level (range)*Median change (%)
CRP (mg/dL)381.3 (0.5-2.6)0.2 (0.1-0.8)−79
IL-6 (pg/mL)3112.0 (1.6-33.0)4,831 (3,450-8,637)48,071
sgp130 (ng/mL)31136 (106-165)158 (127-176)9.4
sEGFR (ng/mL)3133.8 (27.1-42.5)35.7 (27.3-42.8)−0.1
IP10 (ng/mL)310.6 (0.4-0.8)0.9 (0.6-1.3)48
NSE (μg/L)114.8 (2.2-34.0)4.5 (1.0-33.9)−28
ChrA (units/L)1114.8 (12.2-15.9)16.9 (11.9-23.4)20

Abbreviations: ChrA, chromogranin A; NSE, neuron-specific enolase.

  • *Among the subset of patients with both baseline and posttreatment measurements.

  • Posttreatment CRP was measured after three cycles (6 wk); all other markers were measured after two cycles (4 wk).